金斯瑞生物科技(01548.HK):控股股東擬向高瓴旗下公司轉讓3%股份
格隆匯5月14日丨金斯瑞生物科技(01548.HK)公佈,公司已獲公司控股股東Genscript Corporation(“GS Corp”)吿知,於2021年5月14日(下午12時正後及於下午交易時段前),GS Corp與GNS Holdings Limited(“買方”)就轉讓公司股份訂立一份協議,據此,買方同意以每股18.658港元向GS Corp購買約6178.91萬股股份,佔經股份發行擴大的公司現有已發行股本(假設有關發行已完成)約3.00%。
買方為根據開曼羣島法律成立的公司。高瓴資本管理有限公司為買方的唯一投資管理人。完成後(假設股份發行於完成前完成),買方將持有公司股份約1.65億股,佔公司總股本的8.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.